BioArctic AB (publ) (BIOA-B.ST)
SEK 164.6
(1.6%)
SEK 164.6
(1.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 89.62 Million SEK | -44.64% |
| 2022 | 161.9 Million SEK | 50.0% |
| 2021 | 107.93 Million SEK | 14.31% |
| 2020 | 94.42 Million SEK | -3.91% |
| 2019 | 98.26 Million SEK | 18.69% |
| 2018 | 82.78 Million SEK | -29.3% |
| 2017 | 117.09 Million SEK | 161.52% |
| 2016 | 44.77 Million SEK | 20.12% |
| 2015 | 37.27 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 120.46 Million SEK | 20.27% |
| 2024 Q1 | 100.5 Million SEK | 252.68% |
| 2023 Q1 | 62.7 Million SEK | 60.35% |
| 2023 Q4 | 28.49 Million SEK | -54.3% |
| 2023 Q2 | 88.04 Million SEK | 40.42% |
| 2023 Q3 | 62.36 Million SEK | -29.17% |
| 2023 FY | 89.62 Million SEK | -44.64% |
| 2022 Q3 | 54.3 Million SEK | 52.46% |
| 2022 FY | 161.9 Million SEK | 50.0% |
| 2022 Q4 | 39.1 Million SEK | -27.99% |
| 2022 Q2 | 35.61 Million SEK | 8.32% |
| 2022 Q1 | 32.88 Million SEK | 18.85% |
| 2021 Q2 | 27.76 Million SEK | 10.98% |
| 2021 Q1 | 25.02 Million SEK | 11.46% |
| 2021 Q4 | 27.66 Million SEK | 0.69% |
| 2021 Q3 | 27.47 Million SEK | -1.05% |
| 2021 FY | 107.93 Million SEK | 14.31% |
| 2020 Q3 | 20.59 Million SEK | -29.55% |
| 2020 Q4 | 22.44 Million SEK | 9.02% |
| 2020 FY | 94.42 Million SEK | -3.91% |
| 2020 Q1 | 22.15 Million SEK | -20.82% |
| 2020 Q2 | 29.23 Million SEK | 31.96% |
| 2019 FY | 98.26 Million SEK | 18.69% |
| 2019 Q4 | 27.97 Million SEK | 58.46% |
| 2019 Q3 | 17.65 Million SEK | -51.66% |
| 2019 Q2 | 36.51 Million SEK | 126.61% |
| 2019 Q1 | 16.11 Million SEK | -59.65% |
| 2018 FY | 82.78 Million SEK | -29.3% |
| 2018 Q2 | 17.4 Million SEK | -47.89% |
| 2018 Q4 | 39.93 Million SEK | 119.63% |
| 2018 Q1 | 33.39 Million SEK | 3.6% |
| 2018 Q3 | 18.18 Million SEK | 4.48% |
| 2017 Q3 | 30.87 Million SEK | 122.88% |
| 2017 FY | 117.09 Million SEK | 161.52% |
| 2017 Q4 | 32.23 Million SEK | 4.42% |
| 2017 Q2 | 13.85 Million SEK | -43.32% |
| 2017 Q1 | 24.44 Million SEK | 124.26% |
| 2016 Q1 | 11.24 Million SEK | 0.0% |
| 2016 FY | 44.77 Million SEK | 20.12% |
| 2016 Q4 | 10.89 Million SEK | -4.21% |
| 2016 Q3 | 11.37 Million SEK | -7.08% |
| 2016 Q2 | 12.24 Million SEK | 8.84% |
| 2015 FY | 37.27 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 94.081% |
| AcouSort AB (publ) | 25.87 Million SEK | -246.371% |
| Active Biotech AB (publ) | 44.8 Million SEK | -100.02% |
| Alzinova AB (publ) | 36.39 Million SEK | -146.255% |
| Amniotics AB (publ) | 29.07 Million SEK | -208.293% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -511.663% |
| Camurus AB (publ) | 1.05 Billion SEK | 91.542% |
| Cantargia AB (publ) | 290.01 Million SEK | 69.096% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -309.349% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -216.409% |
| Genovis AB (publ.) | 88.19 Million SEK | -1.621% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 22.113% |
| Mendus AB (publ) | 129.13 Million SEK | 30.595% |
| Kancera AB (publ) | 63.07 Million SEK | -42.091% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1523.972% |
| LIDDS AB (publ) | 27.75 Million SEK | -222.957% |
| Lipum AB (publ) | 37.3 Million SEK | -140.242% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1135.553% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 34.055% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -446.473% |
| NextCell Pharma AB | -576.01 Thousand SEK | 15659.73% |
| OncoZenge AB (publ) | 15.9 Million SEK | -463.515% |
| Saniona AB (publ) | 1.07 Million SEK | -8221.913% |
| Simris Alg AB (publ) | 38.64 Million SEK | -131.942% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 72.123% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 74.938% |
| Xintela AB (publ) | 57.31 Million SEK | -56.373% |
| Ziccum AB (publ) | 27.87 Million SEK | -221.497% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1133.173% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 50.682% |
| CombiGene AB (publ) | 44.14 Million SEK | -103.033% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 37.318% |
| Intervacc AB (publ) | 79.78 Million SEK | -12.336% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 70.814% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -110.234% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -406.854% |
| Corline Biomedical AB | 30.16 Million SEK | -197.093% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -54.447% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -7.765% |
| Aptahem AB (publ) | 10.01 Million SEK | -795.111% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 33.459% |
| Fluicell AB (publ) | 28.61 Million SEK | -213.195% |
| Biovica International AB (publ) | 133.72 Million SEK | 32.975% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -352.89% |
| Abliva AB (publ) | 27.86 Million SEK | -221.636% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 53.681% |
| 2cureX AB (publ) | 36.51 Million SEK | -145.432% |
| I-Tech AB | 40.14 Million SEK | -123.242% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 89.572% |
| Cyxone AB (publ) | 28.21 Million SEK | -217.669% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 18.05% |
| Biosergen AB | 26.8 Million SEK | -234.317% |
| Nanologica AB (publ) | 69.88 Million SEK | -28.246% |
| SynAct Pharma AB | 224.49 Million SEK | 60.076% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -102.886% |
| BioInvent International AB (publ) | 441.4 Million SEK | 79.695% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -274.159% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 69.067% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1040.834% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 19.192% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -509.707% |